The global rivastigmine transdermal patches market is anticipated to grow at a CAGR of 6.5% during the forecast period (2022-2028). Parkinson's disease (PD) and Alzheimer's disease are both neurological conditions caused by neurodegeneration (gradual damage to brain cells). Globally, disability and mortality due to Parkinson’s disease are increasing faster than any other neurological disorder. According to the World Health Organization (WHO), the prevalence of PD has doubled in the past 25 years. Global estimates in 2019 showed over 8.5 million individuals with PD. Further, according to Mayo Clinics, globally around 50 million people suffer from dementia, and between 60% and 70% are estimated to have Alzheimer's disease. Such diseases have a major impact on the quality of life of both the patient and the caregiver. Given the short life expectancy following a diagnosis of AD, and the progressive nature of the disease, treatments that stabilize symptoms or delay their progression have important benefits on the quality of life for patients and their caregivers. Cholinesterase inhibitors constitute one of the mainstays of treatment for such diseases. However, gastrointestinal side effects, difficulty accessing therapeutic doses, and poor patient compliance have been identified as barriers to effective treatment with these substances.
Browse the full report description of “Rivastigmine Transdermal Patches Market Size, Share & Trends Analysis Report, By Type (4.6mg/24hr, 9.5mg/24hr, and 13.3 mg/24hr), By Application (Alzheimer’s Disease, Parkinson’s Disease, and Others), Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/rivastigmine-transdermal-patches-market
The rivastigmine transdermal patch provides a viable solution for all such problems as it supports the continuous delivery of drugs through the skin into the bloodstream in a non-invasive way, avoiding the fluctuations in plasma concentration associated with oral administration. It causes reduced side effects and results in easier access to expected target doses. These benefits, along with other practical advantages of the transdermal patch, contribute to enhanced patient compliance and therefore continuously evolve popular among health providers and caregivers of patients.
On April 12, 2022 — Luye Pharma Group announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration has accepted the Marketing Authorization Application for the company’s investigational Rivastigmine Twice Weekly Transdermal Patch indicated for treating Alzheimer’s disease of mild to moderate symptoms. The product has already received marketing authorization in multiple European countries.
In May 2022, the World Health Assembly endorsed the Intersectoral global action plan on epilepsy and other neurological disorders 2022–2031. The action plan will address the challenges and gaps in providing care and services for people with epilepsy and other neurological disorders such as PD that exist worldwide and ensure a comprehensive, coordinated response across sectors.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Type
o By Application
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- Amneal Pharmaceuticals Inc., Luye Pharma Group, Novartis International AG, Ono Pharmaceutical Co., Ltd., and Zydus Healthcare Ltd.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Rivastigmine Transdermal Patches Market Report by Segment
By Type
By Application
Global Rivastigmine Transdermal Patches Market Report by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/rivastigmine-transdermal-patches-market